Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-05
2007-06-05
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S228500, C514S253030, C544S060000, C544S361000, C544S364000, C548S559000
Reexamination Certificate
active
10479109
ABSTRACT:
The disclosure provides methods for the treatment and prevention of periodontal disease. In preferred embodiments, the invention provides for local treatment of periodontal tissues with a pharmaceutical composition including an immune response modifier (IRM) selected from the group of immune response modifiers comprising imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphtyridine amines, oxazoloquinoline amines, thiazoloquinoline amines and 1,2-bridged imidazopyridine amines.
REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gerster
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Llindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5494916 (1996-02-01), Lindstrom et al.
patent: 5525612 (1996-06-01), Gerster
patent: 5693811 (1997-12-01), Lindstrom
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster et al.
patent: 5854257 (1998-12-01), Armitage et al.
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6200592 (2001-03-01), Tomai et al.
patent: 6245766 (2001-06-01), Watsky
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6486168 (2002-11-01), Skwierczynski et al.
patent: 6518265 (2003-02-01), Kato et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6610319 (2003-08-01), Tomai et al.
patent: 6656938 (2003-12-01), Crooks et al.
patent: 6660735 (2003-12-01), Crooks et al.
patent: 6660747 (2003-12-01), Crooks et al.
patent: 6664260 (2003-12-01), Charles et al.
patent: 6664264 (2003-12-01), Dellaria et al.
patent: 6664265 (2003-12-01), Crooks et al.
patent: 6667312 (2003-12-01), Bonk et al.
patent: 6670372 (2003-12-01), Charles et al.
patent: 6677347 (2004-01-01), Crooks et al.
patent: 6677348 (2004-01-01), Heppner et al.
patent: 6677349 (2004-01-01), Griesgraber
patent: 6683088 (2004-01-01), Crooks et al.
patent: 6696076 (2004-02-01), Tomai et al.
patent: 6894060 (2005-05-01), Slade
patent: 2002/0016332 (2002-02-01), Slade
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 2002/0110840 (2002-08-01), Tomai et al.
patent: 2003/0130299 (2003-07-01), Crooks et al.
patent: 2003/0133913 (2003-07-01), Tomai et al.
patent: 2003/0139364 (2003-07-01), Krieg et al.
patent: 2003/0161797 (2003-08-01), Miller et al.
patent: 2003/0199538 (2003-10-01), Skwierczynski et al.
patent: 2003/0232852 (2003-12-01), Lindstrom et al.
patent: 2004/0010007 (2004-01-01), Dellaria et al.
patent: 2004/0014779 (2004-01-01), Gorden et al.
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 00/76505 (2000-12-01), None
patent: WO 00/76518 (2000-12-01), None
patent: WO 02/07725 (2002-01-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 03/103584 (2003-12-01), None
Bernstein, J of Infectious diseases, vol. 183(6), pp. 844-849, 2001.
Diaz-Arrastia, Clinical Cancer Research, 7(10), pp. 3031-3033, 2001.
Spruance, J of Infectious Diseases, 184(2), pp. 196-200, 2001.
Soria, Chemical Abstracts 137:163261, abstract of Therapeutics, 38(10), 476-481, 2000.
Bishop, J of Immunology, 165(10), 5552-5557, 2000.
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2. A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society, 102, pp. 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniques, Jun./Jul. 78, 1983.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology, vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem, 15, pp. 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem., 11, pp. 87-92 (1968).
Baranov, et al.,Chem. Abs. 85, 94362, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem., 18, pp. 1537-1540 (1981).
Chollet, et al, “Development of a Topically Active Imiquimod Formulation”,Pharmaceutical Development and Technology, 4(1), pp. 35-43 (1999).
Izumi, et al., “1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines”,Bioorganic&Medicinal Chemistry, 11, pp. 2541-2550 (2003).
Kornman, Kenneth S., “Host Modulation as a Therapeutic Strategy in the Treatment of Periodontal Disease”,Clinical Infectious Diseases, vol. 28, No. 3, 520-526, Mar. 1999.
Zambon, J.J., “Periodontal Disease: Microbial Facors”,Ann. Peridontol, vol. 1, pp. 879-825, 1996.
Beck, et al, “Dental Infections and Atherosclerosis”,American Heart Journal, 13, pp. 528-533, 1999.
Loesche, et al, Treatment Paradigms in Pariodontal Disease,Compen. Contin. Educ. Dental, vol. 18 (3), p p. 221-226 and 228-230, 1997.
Page, et al, “Advances in the Pathogenesis of Periodontitis: Summary of Developments, Clinical Implications and Future Directions”,Periodontology 2000, vol. 14, 216-248, 1997.
Mathur, et al, “Cell-Mediated, Immune System Regulation in Periodontal Disease”,Critical Rev. Oral. Bio. Med., vol. 8, pp. 76-89, 1997.
Seymour G. J. et al, “Cellular Immunity and Hypersensitivity as Components of Periodontal Destruction”,Oral Dis., vol. 2 (1), pp. 76-101, 1996.
Bartova, et al, “TH1 and TH2 Cytokine Profile in Patients with Earlyonset Periodontitis and their Healthy Siblings”,Mediators Inflamm., vol. 9(2), pp. 115-120, 2000.
Assuma, et al, “IL-1 and TNF Antagonists Inhibit the Inflammatory Response and Bone Loss in Experimental Periodontitis”,Journal of Immunology, vol. 160, pp. 403-409, 2000.
Takeichi, et al, “Cytokine Profiles of T-Lymhocytes from Gingivaltissues with Pathological Pocketing”,J. Dent. Res., vol. 79(8), pp. 1548-1555, Aug. 2000.
Wagner, et al, “Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod”,Cellular Immunology, vol. 191, pp. 10-19, 1999.
Mitra Sumita B.
Shelburne Charles E.
Tomai Mark A.
LandOfFree
Methods for the treatment of periodontal disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of periodontal disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of periodontal disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3870835